RAVICTI (glycerol phenylbutyrate) oral liquid. Initial U.S. Approval: 1996

RAVICTI (glycerol phenylbutyrate) oral liquid. Initial U.S. Approval: 1996

RAVICTI (glycerol phenylbutyrate) is a nitrogen-binding agent indicated for chronic management of patients 2 years of age and older with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements.
Oral liquid: 1.1 g/mL of glycerol phenylbutyrate
Manufactured By: Horizon Therapeutics
Prescribing Information URL: Click Here

Access to RAVICTI ® (glycerol phenylbutyrate) oral liquid: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Glycerol phenylbutyrate (USAN), trade name Ravicti, is a medication used in the treatment of certain inborn urea cycle disorders. The medication works by preventing the harmful buildup of ammonia in the body. It is an FDA-approved prescription drug in the US.


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.